Effect of Decrease in Both Postprandial Blood Glucose (PBG) and Fasting Blood Glucose (FBG) Levels in Normal Beagle Dogs with Nateglinide Enteric Coated Granules and Immediate Release Tablets
スポンサーリンク
概要
- 論文の詳細を見る
Nateglinide is a new quick action/short duration (QRSD) type of oral blood glucose regulator, and nateglinide immediate release tablets are used for patients with mild diabetes under the trade name of Fastic tablets. In this study, we attempted to determine if it was possible to control both post-prandial blood glucose level (PBG) and fasting blood glucose level (FBG) for moderate or severe diabetes through controlled release of nateglinide. Enteric coated granules were selected for the administration form for controlled release of nateglinide, and three types of enteric coated granules were prepared having dissolution pH values of 5.5, 6.5 and 7.2. The three types of enteric coated granules were each administered separately or the enteric coated granules having an dissolution pH of 6.5 were administered simultaneous to administration of nateglinide immediate release tablets to normal beagle dogs just before feeding followed by measurement of plasma nateglinide concentration, plasma insulin concentration and blood glucose level. In the case of administering enteric coated granules alone (nateglinide: 9mg/kg), the absorption of nateglinide was confirmed to tend to be delayed as the dissolution pH increased. In the case of an dissolution pH of 5.5, decreases in both PBG and FBG were observed. In the case of dissolution pH values of 6.5 and 7.2, only decrease in FBG was observed. In case of nateglinide immediate release tablets (nateglinide: 9mg/kg), only decrease in PBG was observed. Decreases in both PBG and FBG were observed in the case of simultaneous administration of dissolution pH 6.5 enteric coated granules and nateglinide immediate release tablets just before feeding (nateglinide: 90mg/head+60mg/head). A correlation was observed between plasma nateglinide concentrations and blood glucose levels. On the other hand, there were no correlations observed between changes in plasma insulin concentrations and blood glucose levels. In case of nateglinide immediate release tablets (nateglinide: 150mg/head), Decreases in both PBG and FBG were observed. However, the nateglinide controlled release formulation is more useful than the nateglinide immediate release tablets from the view point of avoidance of side effect, or of easy control of both PBG and FBG. On the basis of these results, the design of a controlled release formulation that contains nateglinide was suggested to enable control of both PBG and FBG for moderate and severe diabetes patients.
- 社団法人日本薬学会の論文
- 2006-04-01
著者
-
Okano A
National Institute Of Livestock And Grassland Science
-
Okano A
Pharmaceutical Research Laboratories Ajinomoto Co. Inc.
-
Okano Akira
Pharmaceutical Research Laboratories Ajinomoto Co. Inc
-
Makino Chisato
Pharmaceutical Research Laboratories, Ajinomoto Co., Inc.
-
Sakai Hidetoshi
Pharmaceutical Research Laboratories, Ajinomoto Co., Inc.
-
Yabuki Akira
Pharmaceutical Research Laboratories, Ajinomoto Co., Inc.
-
NINOMIYA Nobutaka
Pharmaceutical Research Laboratories, Ajinomoto Co., Inc.
-
ORITA Haruo
Pharmaceutical Research Laboratories, Ajinomoto Co., Inc.
-
Ninomiya Nobutaka
Pharmaceutical Research Laboratories Ajinomoto Co. Inc.
-
Orita Haruo
Pharmaceutical Research Laboratories Ajinomoto Co. Inc.
関連論文
- Design of Nateglinide Controlled Release Tablet Containing Erosion Matrix Tablet and Multiple Administration Study in Normal Beagle Dogs
- Effect of Decrease in Both Postprandial Blood Glucose (PBG) and Fasting Blood Glucose (FBG) Levels in Normal Beagle Dogs with Nateglinide Enteric Coated Granules and Immediate Release Tablets
- Interleukin-6 and Granulocyte Colony-stimulating Factor Synergistically Increase Peripheral Blood Progenitor Cells in Myelosuppressive Mice
- Nateglinide Controlled Release Tablet Containing Compressionable Enteric Coated Granules
- Evaluation of Antivascular and Antimitotic Effects Tubulin Binding Agents in Solid Tumor Therapy
- A Novel Combretastatin A-4 Derivative, AC-7700, Shows Marked Antitumor Activity against Advanced Solid Tumors and Orthotopically Transplanted Tumors
- Nateglinide Suppresses Postprandial Hypertriglyceridemia in Zucker Fatty Rats and Goto-Kakizaki Rats : Comparison with Voglibose and Glibenclamide
- Production of Trophoblastic Vesicles Derived From Day 7 and 8 Blastocysts of In Vitro Origin and the Effect of Intrauterine Transfer on the Interestrous Intervals in Japanese Black Heifers
- Apoptosis in the Porcine Uterine Endometrium During the Estrous Cycle, Early Pregnancy and Post Partum